agen stock price target

Should you buy Agen stock?

Should You Buy Robinhood Stock When It IPOs?

• The business is growing rapidly. Robinhood is one of the fastest-growing businesses in the world. ...
• Know before you buy. The company's business is growing quickly, but it's doing so in ways that investors will have to watch over time.
• Expect a steep valuation. ...

What does target price mean in stocks?

Target Price in Stocks

• Target Price Advantage. A target price is an estimate of where an analyst thinks a stock will go. ...
• Target Price Disadvantage. The analysts could be wrong. ...
• Advantage of Starting from the Actual Price. ...
• Disadvantage of Starting from the Actual Price. ...

How to calculate target price?

What to Analyze

• Industry Analysis. There are publicly available sources of information for almost any industry. ...
• Business Model Analysis. You should focus on a company's strengths and weaknesses. ...
• Financial Strength. ...
• Management Quality. ...
• Growth Analysis. ...
• Valuations. ...
• Target Price. ...

How much are target stocks?

Target stock price target raised to $353 from $305 at Deutsche Bank Mar. 2, 2022 at 7:53 a.m. ET by Tomi Kilgore Target stock price target raised to $290 from $262 at J.P. Morgan

Is AGEN stock a good buy?

Agenus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

How high will AGEN stock go?

Stock Price Forecast The 2 analysts offering 12-month price forecasts for Agenus Inc have a median target of 7.50, with a high estimate of 8.00 and a low estimate of 7.00. The median estimate represents a +177.26% increase from the last price of 2.71.

Why did AGEN go down?

Agenus (AGEN) has been beaten down lately with too much selling pressure. While the stock has lost 33.3% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.

Why is AGEN stock up?

In response to the impressive clinical progress of Agenus' anti-cancer checkpoint inhibitor platform, Wainwright raised its 12-month price target on the biotech's shares to $14 ahead of the opening bell this morning.

What does agenus company do?

Agenus is an immuno-oncology company focused on the discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer.

When did agenus go public?

Agenus is registered under the ticker NASDAQ:AGEN . Their stock opened with $18.00 in its Feb 11, 2000 IPO.

Is agenus a good company?

It's a small enough company to get that innovation and opportunity to work with multiple teams. If you are energetic and willing to put extra efforts into your ideas, you can definitely do it at your expense. If you put in the time and effort you can get visibility and opportunity to collaborate on different projects.

What is Agenus's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Agenus stock is Buy based on the current 2 buy ratings for...

Do Wall Street analysts like Agenus more than its competitors?

Analysts like Agenus stock more than the stock of other Medical companies. The consensus rating score for Agenus is 3.00 while the average consensu...

Do MarketBeat users like Agenus more than its competitors?

MarketBeat users like Agenus stock more than the stock of other Medical companies. 70.63% of MarketBeat users gave Agenus an outperform vote while...

Does Agenus's stock price have much upside?

According to analysts, Agenus's stock has a predicted upside of 258.89% based on their 12-month price targets.

Should I buy or sell Agenus stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last twelve months. There are currently 2...

What is Agenus' stock price forecast for 2022?

2 equities research analysts have issued 12 month price objectives for Agenus' stock. Their forecasts range from $8.00 to $14.00. On average, they...

How has Agenus' stock price performed in 2022?

Agenus' stock was trading at $3.22 at the start of the year. Since then, AGEN stock has decreased by 54.7% and is now trading at $1.46. View the b...

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Agenus .

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) released its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.19) EPS for the quarte...

Who are Agenus' key executives?

Agenus' management team includes the following people: Dr. Garo H. Armen Ph.D. , Founder, Exec. Chairman & CEO (Age 69, Pay $1.07M) Ms. Christin...

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com . Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts...

Who are some of Agenus' key competitors?

Some companies that are related to Agenus include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceuti...

What other stocks do shareholders of Agenus own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agenus investors own include (ROSG) (ROSG) , Exelixis (EX...

Component Grades

We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.

AGEN Broker Recommendations Summary

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

What is Agen2373?

AGEN2373 is advancing in a Phase 1 clinical trial against solid tumors. About AgenusAgenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer.

Who is the chief legal officer of Agenus?

Why Agenus Stock Sank on Tuesday. Agenus announced in a tersely worded regulatory filing that chief legal and compliance officer Adam Krauss has served notice that he will be vacating his position, effective this Friday, July 30. Krauss was not a longtime Agenus employee.

When is Agenus meeting 2021?

LEXINGTON, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that its annual meeting will begin at 5:00 p.m. ET on June 15, 2021 and will be conducted in a virtual format only. Registration for attendees will start at 4:45 p.m. ET. To participate in the Annual Shareholders Meeting, sha

Is Agenus an immunotherapy company?

LEXINGTON, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today presented data demonstrating the differentiation of balstilimab as an anti-PD-1 antibody as well as data from a Phase 1 clinical trial of AGEN2373, a CD137 agonist antibody, at the American Society of Clinical Oncology (ASCO) Annual Me

What is Agenus Inc?

Agenus Inc., formerly known as Antigenics Inc., is engaged in the discovery, development and commercialization of immunotherapeutics for the treatment of life threatening and chronic medical conditions. Immunotherapeutics are drugs that work by modulating the immune system to fight diseases. The Company's product line includes Oncophage vaccine, a patient-specific therapeutic cancer vaccine. The Company is also developing Prophage, patient-specific therapeutic cancer vaccine; QS-21, vaccine adjuvant; and HerpV, a polyvalent off-the-shelf therapeutic heat shock protein-based vaccine for treatment of genital herpes which are all in the clinical testing stages. Agenus Inc. is headquartered in Lexington, Massachusetts.

What is an X industry?

The X Industry (aka Expanded Industry) is a subset of the M (Medium Sized) Industry, which is a subset of the larger Sector category, which is used to classify all of the stocks in the Zacks Universe. The Zacks database contains over 10,000 stocks.

What is value scorecard?

The Value Scorecard identifies the stocks most likely to outperform based on its valuation metrics. This list of both classic and unconventional valuation items helps separate which stocks are overvalued, rightly lowly valued, and temporarily undervalued which are poised to move higher.

What is a strong weekly advance?

A strong weekly advance (especially when accompanied by increased volume) is a sought after metric for putting potential momentum stocks onto one's radar. Others will look for a pullback on the week as a good entry point, assuming the longer-term price changes (4 week, 12 weeks, etc.) are strong.

Is a B better than a C?

An A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. Value Score A. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B.